Revertant Mosaicism in Recessive Dystrophic Epidermolysis Bullosa
Noor Almaani,Nikoletta Nagy,Lu Liu,Patricia J.C. Dopping-Hepenstal,Joey E. Lai‐Cheong,Suzanne Clements,Tanasit Techanukul,Akio Tanaka,Jemima E. Mellerio,John A. McGrath
DOI: https://doi.org/10.1038/jid.2010.64
2010-01-01
Abstract:Revertant mosaicism refers to the presence of two genetically heterogeneous populations of cells as a result of spontaneous genetic correction during mitosis (Hall, 1988Hall J.G. Review and hypotheses: somatic mosaicism: observations related to clinical genetics.Am J Hum Genet. 1988; 43: 355-363PubMed Google Scholar; Jonkman et al., 1997Jonkman M.F. Scheffer H. Stulp R. et al.Revertant mosaicism in epidermolysis bullosa caused by mitotic gene conversion.Cell. 1997; 88: 543-551Abstract Full Text Full Text PDF PubMed Scopus (189) Google Scholar). This phenomenon has been reported in several inherited diseases, including severe combined immunodeficiency, Bloom's syndrome, Fanconi's anemia, X-linked Wiscott–Aldrich syndrome, Duchenne muscular dystrophy, and tyrosinemia type I (Hirschhorn, 2003Hirschhorn R. In vivo reversion to normal of inherited mutations in humans.J Med Genet. 2003; 40: 721-728Crossref PubMed Scopus (138) Google Scholar). With regard to genodermatoses, cutaneous revertant mosaicism has been described in epidermolysis bullosa (EB) (Fine et al., 2008Fine J.D. Eady R.A. Bauer E.A. et al.The classification of inherited epidermolysis bullosa (EB): Report of the third international consensus meeting on diagnosis and classification of EB.J Am Acad Dermatol. 2008; 58: 931-950Abstract Full Text Full Text PDF PubMed Scopus (672) Google Scholar). Notably, in vivo reversion of mutations in LAMB3, COL17A1, and KRT14 has underscored cutaneous mosaicism in non-Herlitz junctional EB and EB simplex, respectively (Darling et al., 1999Darling T.N. Yee C. Bauer J.W. et al.Revertant mosaicism: partial correction of a germ-line mutation in COL17A1 by a frame-restoring mutation.J Clin Invest. 1999; 103: 1371-1377Crossref PubMed Scopus (57) Google Scholar; Schuilenga-Hut et al., 2002Schuilenga-Hut P.H. Scheffer H. Pas H.H. et al.Partial revertant mosaicism of keratin 14 in a patient with recessive epidermolysis bullosa simplex.J Invest Dermatol. 2002; 118: 626-630Crossref PubMed Scopus (53) Google Scholar; Smith et al., 2004Smith F.J. Morley S.M. McLean W.H. Novel mechanism of revertant mosaicism in Dowling-Meara epidermolysis bullosa simplex.J Invest Dermatol. 2004; 122: 73-77Abstract Full Text Full Text PDF PubMed Scopus (48) Google Scholar; Pasmooij et al., 2005Pasmooij A.M. Pas H.H. Deviaene F.C. et al.Multiple correcting COL17A1 mutations in patients with revertant mosaicism of epidermolysis bullosa.Am J Hum Genet. 2005; 77: 727-740Abstract Full Text Full Text PDF PubMed Scopus (60) Google Scholar, Pasmooij et al., 2007Pasmooij A.M. Pas H.H. Bolling M.C. et al.Revertant mosaicism in junctional epidermolysis bullosa due to multiple correcting second-site mutations in LAMB3.J Clin Invest. 2007; 117: 1240-1248Crossref PubMed Scopus (76) Google Scholar; Jonkman and Pasmooij, 2009Jonkman M.F. Pasmooij A.M. Revertant mosaicism—patchwork in the skin.N Engl J Med. 2009; 360: 1680-1682Crossref PubMed Scopus (64) Google Scholar). Of potential clinical interest, such genetic events may not be that rare—perhaps occurring in up to one-third of cases of non-Herlitz junctional EB (Jonkman and Pasmooij, 2009Jonkman M.F. Pasmooij A.M. Revertant mosaicism—patchwork in the skin.N Engl J Med. 2009; 360: 1680-1682Crossref PubMed Scopus (64) Google Scholar). Multiple corrective mechanisms have been proposed or observed, including back mutations, intragenic crossovers, mitotic gene conversions, and second-site mutations (Jonkman et al., 1997Jonkman M.F. Scheffer H. Stulp R. et al.Revertant mosaicism in epidermolysis bullosa caused by mitotic gene conversion.Cell. 1997; 88: 543-551Abstract Full Text Full Text PDF PubMed Scopus (189) Google Scholar; Pasmooij et al., 2005Pasmooij A.M. Pas H.H. Deviaene F.C. et al.Multiple correcting COL17A1 mutations in patients with revertant mosaicism of epidermolysis bullosa.Am J Hum Genet. 2005; 77: 727-740Abstract Full Text Full Text PDF PubMed Scopus (60) Google Scholar; Frank and Happle, 2007Frank J. Happle R. Cutaneous mosaicism: right before our eyes.J Clin Invest. 2007; 117: 1216-1219Crossref PubMed Scopus (22) Google Scholar). Indeed, several different corrective processes can occur in the same patient (Jonkman and Pasmooij, 2009Jonkman M.F. Pasmooij A.M. Revertant mosaicism—patchwork in the skin.N Engl J Med. 2009; 360: 1680-1682Crossref PubMed Scopus (64) Google Scholar). The implications for phenotype, however, depend on several factors, including the timing and extent of the revertant mosaicism. Here we report a further example of revertant mosaicism in a different sub-type of EB, with probable intragenic crossover in the COL7A1 gene leading to restoration of basement membrane collagen VII and anchoring fibrils in a patch of skin in an individual with recessive dystrophic EB. The proband is a 41-year-old Caucasian British man with severe generalized recessive dystrophic EB (Fine et al., 2008Fine J.D. Eady R.A. Bauer E.A. et al.The classification of inherited epidermolysis bullosa (EB): Report of the third international consensus meeting on diagnosis and classification of EB.J Am Acad Dermatol. 2008; 58: 931-950Abstract Full Text Full Text PDF PubMed Scopus (672) Google Scholar). He has mutilating scars with bilateral mitten deformities and a history of recurrent squamous cell carcinomas. His skin is prone to trauma-induced blistering, although for as long as he can remember, two small patches of skin on his left wrist and right shin never seem to blister despite repeated trauma. Examination of these sites revealed areas approximately 8 × 5cm2 that resembled the normal skin in appearance and texture (Figure 1a and b). To explain the phenotypic heterogeneity, and following ethics committee approval (St Thomas’ Hospital Ethics Committee: 07/H0802/104) and informed consent and in accordance with the Declaration of Helsinki principles, skin from the left wrist was investigated with biopsy specimens taken from both the blister-prone area (unreverted) and the normal-appearing skin (reverted). Immunolabeling for collagen VII (clone LH 7.2; Sigma-Aldrich, Poole, UK) and transmission electron microscopy were performed as described elsewhere (McGrath et al., 1993McGrath J.A. Ishida-Yamamoto A. O’Grady A. et al.Structural variations in anchoring fibrils in dystrophic epidermolysis bullosa: correlation with type VII collagen expression.J Invest Dermatol. 1993; 100: 366-372Abstract Full Text PDF PubMed Google Scholar) and the results are illustrated in Figure 1c–e. Sequencing of peripheral leukocyte genomic DNA revealed that the patient is a compound heterozygote for two loss-of-function mutations in COL7A1, c.1732C>T (p.Arg578X) in exon 13 (maternal) and c.7786delG (p.Gly2593fsX4) in exon 104 (paternal) (Figure 2a). Both of these are recurrent mutations within the white British population (Mellerio et al., 1997Mellerio J.E. Dunnill M.G. Allison W. et al.Recurrent mutations in the type VII collagen gene (COL7A1) in patients with recessive dystrophic epidermolysis bullosa.J Invest Dermatol. 1997; 109: 246-249Crossref PubMed Scopus (46) Google Scholar).Figure 2Revertant mosaicism is likely to result from intragenic crossover in COL7A1. (a) Sequencing of genomic DNA (gDNA) from the patient's unreverted skin that reveals compound heterozygosity for the mutations c.1732C>T (p.Arg578X) in exon 13 and c.7786delG (p.Gly2593fsX4) in exon 104, as also delineated in peripheral blood leukocyte genomic DNA (not illustrated). Both mutations are present in genomic DNA from the reverted skin (center panels). Normal control genomic DNA wild-type sequences are also illustrated. (Genomic DNA sequence traces across the mutation c.7786delG are shown in flipped reverse orientation for uniformity.) (b) Sequencing of complementary DNA (cDNA) extracted from the patient's unreverted skin showing the presence of both loss-of-function mutations. In contrast, in the patient's reverted skin, the nonsense mutation can still be detected, but across the site of the frameshift mutation in exon 104, only the wild-type sequence is evident. Normal control cDNA wild-type sequences are also illustrated. (c) Real-time reverse transcriptase-PCR showing barely detectable COL7A1 gene expression in the patient's skin or cultured fibroblasts derived from the unreverted area. In contrast, in the reverted skin, COL7A1 gene expression levels are similar to those seen in the patient's brother (a heterozygous carrier of one COL7A1 mutation), but cultured fibroblasts from the reverted area fail to show a similar increase in COL7A1 gene expression to that seen in the brother. (d) The maternal nonsense mutation in exon 13 occurs on the same allele bearing a G nucleotide for a PvuII polymorphism in exon 21, but in the reverted skin the wild-type sequence for exon 104 occurs on the same allele bearing a paternal A nucleotide for the exon 21 polymorphism. This suggests that intragenic crossover has occurred somewhere between exons 21 and 104, and that the patient has restored one functional COL7A1 allele that is capable of generating collagen VII protein at the dermal–epidermal junction, as well as morphologically recognizable anchoring fibrils.View Large Image Figure ViewerDownload (PPT) To explain the heterogeneous skin phenotype, genomic DNA and RNA were extracted from whole skin from both unreverted and reverted areas using standard kits (DNA Extraction Minikit and RNAEasy Minikit, Qiagen, Crawley, UK), as well as from cultured fibroblasts from both sites (TRIzol, Invitrogen, Paisley, UK) using the manufacturer's protocols. The fibroblast cultures were performed using standard methods (Wong et al., 2008Wong T. Gammon L. Liu L. et al.Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa.J Invest Dermatol. 2008; 128: 2179-2189Crossref PubMed Scopus (181) Google Scholar). cDNA was generated using commercial kits and protocols (IScript cDNA generation kit, Biorad, Hemel Hempstead, UK). Reverse transcriptase-PCR was performed across the sites of both mutations and the results are illustrated in Figure 2b. Real-time reverse transcriptase-PCR was also carried out to assess COL7A1 gene expression in the different skin and cell samples with primers (details available on request) specifically designed to amplify a 200-bp region of the COL7A1 3′UTR (SyberGreen Master Mix, Applied Biosystems, Warrington, UK). Reverse transcriptase-PCR for each cDNA sample was carried out in triplicate and the results are illustrated in Figure 2c. Collectively, these investigations indicated that the reverted skin expressed collagen VII and that anchoring fibrils were present. In addition, the reverse transcriptase-PCR data demonstrated that there was expression of wild-type cDNA spanning the frameshift mutation in exon 104 and that COL7A1 gene expression levels were similar to those seen in the patient's brother who was heterozygous for one mutant COL7A1 allele (Figure 2c). Moreover, the gene correction in the patient's reverted skin appeared to have occurred in keratinocytes rather than fibroblasts. To explore the mechanism of this correction, we performed long-range sequencing of the patient's reverted skin cDNA using LongAmp Taq DNA polymerase (New England Biolabs, Hitchin, UK). We first searched for polymorphisms to distinguish between maternal and paternal alleles and identified differences for a common PvuII polymorphism in exon 21 (c.2817G/A; rs1264194). Although no other potentially informative intragenic polymorphisms were detected, sequencing was able to demonstrate a COL7A1 allele bearing neither mutation (in exon 13/104) in combination with a paternally derived A nucleotide for the exon 21 polymorphism. These data are consistent with intragenic crossover occurring somewhere between exons 21 and 104 (Figure 2d). The net result is the generation of a patch of skin that functions similarly to that seen in a heterozygous carrier for one loss-of-function mutation in COL7A1. The area of potential revertant mosaicism on the patient's right shin was not investigated in this study. Identification of a patch of revertant mosaicism that shows functional properties similar to those of a heterozygous carrier now provides new therapeutic opportunities for patients. Expansion of revertant keratinocytes in non-Herlitz junctional EB and grafting onto unreverted sites have already been attempted (Gostynski et al., 2009Gostynski A. Deviaene F.C. Pasmooij A.M. et al.Adhesive stripping to remove epidermis in junctional epidermolysis bullosa for revertant cell therapy.Br J Dermatol. 2009; 161: 444-447Crossref PubMed Scopus (56) Google Scholar), although low levels of reversion in the graft material led to no appreciable clinical benefit in that case. Nevertheless, this approach represents an exciting possibility for our patient with recessive dystrophic EB. In addition, recent technological advances enabling creation of inducible pluripotent stem cells from keratinocytes also offer new possibilities for translational research (Aasen et al., 2008Aasen T. Raya A. Barrero M.J. et al.Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes.Nat Biotechnol. 2008; 26: 1276-1284Crossref PubMed Scopus (1067) Google Scholar). Thus, the “natural gene therapy” observed in this patient may hold considerable future therapeutic potential. N.A. and N.N. are clinical research fellows, supported by the Dystrophic Epidermolysis Bullosa Research Association (DebRA, UK). We acknowledge financial support from the Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy's and St Thomas’ NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust.